Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

CBSET Chairman Elazer Edelman, MD, PhD, has Received “TCT 2017 Career Achievement Award”

CBSET Inc.
Posted on: 01 Nov 17

CBSET Inc., a non-profit translational research institute that specializes in the advancement of novel therapies, announced today that Internationally renowned cardiologist, Elazer Edelman, MD, PhD, has received the “TCT Career Achievement Award” at TCT 2017 in Denver, Colorado. TCT Directors, Martin B. Leon, MD, and Gregg W. Stone, MD, presented the award.

Dr. Edelman is Chairman of CBSET.

“We are extremely proud to honor Elazer Edelman with the TCT 2017 Career Achievement Award,” said Dr. Leon, CRF Founder and Co-Director of Medical Research and Education. “Over the course of his distinguished career, he has transformed patient care by bringing together experts from various disciplines to create highly effective and clinically relevant solutions to medical problems. His research, which combines his passion for basic science with practical medical training, has contributed to generations of life-changing devices such as bare-metal and drug-eluting stents.”

A lifelong researcher and innovator, Dr. Edelman and his students have been credited as some of the key contributors and pioneers of the coronary stent. His research examining the cellular and molecular mechanisms that produce atherosclerosis and coronary artery disease critically advanced the development and optimization of the first bare-metal stents and subsequent iterations, including drug-eluting stents. His most recent publications have focused on how tissue-engineered cells might be used for the local delivery of growth factors and growth inhibitors in the study of the vascular homeostasis and repair, cancer invasiveness and metastases and the homology between endothelial paracrine and angiocrine regulation in cancer and vascular diseases.

“Dr. Edelman is widely recognized for his vision, leadership, advancement of technological innovations and novel insights into biomedical pathways and vascular responses,” added Dr. Stone, Co-Director of Medical Research and Education at CRF. “Along with his extensive academic, clinical, and medical pursuits, he has devoted a significant amount of his career to mentoring the next generation of researchers and clinicians.”

Dr. Edelman’s research integrates multiple disciplines, including polymer based controlled and modulated drug delivery; growth factor biology and biochemistry; tissue engineering; biomaterials-tissue interactions and the vascular response to injury. He has been deeply devoted to the education and training of colleagues and future generations by mentoring more than 350 graduate students and postdoctoral fellows. He has also authored or co-authored nearly 300 original scientific publications.

Dr. Edelman is currently the Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology at the Massachusetts Institute of Technology (MIT). He is a Professor of Medicine at Harvard Medical School and Senior Attending Physician at Brigham and Women’s Hospital. Dr. Edelman also directs the Harvard-MIT Biomedical Engineering Center (BMEC), dedicated to applying the rigors of the physical sciences to elucidate fundamental biologic processes and mechanisms of disease.

Dr. Edelman received Bachelor of Science degrees in Bioelectrical Engineering and Applied Biology from MIT, a Master’s of Science degree in Electrical Engineering and Computer Sciences from MIT, a degree in medicine from Harvard Medical School and a PhD in Medical Engineering and Medical Physics from MIT. His graduate thesis work, under the direction of Prof. Robert Langer, defined the mathematics of regulated and controlled drug delivery systems.

After receiving his degrees, he completed an internship and residency in Internal Medicine and fellowship in Cardiovascular Medicine, all at the Brigham and Women's Hospital. He subsequently spent six years as a research fellow in the Department of Pathology at Harvard Medical School with Prof. Morris J. Karnovsky working on the biology of vascular repair.

Dr. Edelman is a fellow of the American College of Cardiology, American Heart Association, American Institute for Medical and Biological Engineering, American Society for Clinical Investigation, American Academy of Arts and Sciences, National Academy of Medicine, National Academy of Engineering and National Academy of Inventors. As Chief Scientific Advisor of Science: Translational Medicine and member of the FDA Scientific Board, he has set the tone for the national debate on translational research and innovation.

For more information about CBSET, contact Michael Naimark, Director of Business Development at CBSET: +1-781-541-5627, mnaimark@cbset.org

About CBSET
CBSET Inc. — 500 Shire Way, Lexington, Mass. — is the preclinical research leader in critically important therapeutic fields such as interventional cardiology, renal disease and dialysis, chronic drug-resistant hypertension, women’s health, minimally invasive surgery, orthopedics, biological and synthetic tissue repair, drug delivery, bioresorbable devices, and combination medical device and drug-eluting products. Learn more about CBSET’s expert biomedical research services or please contact us.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171101006109/en/

Business Wire
www.businesswire.com

Last updated on: 01/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.